Clinical implications of dose-dependent cytochrome P-450 drug–drug interactions with antidepressants
✍ Scribed by C. L. DeVane
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 123 KB
- Volume
- 13
- Category
- Article
- ISSN
- 0885-6222
No coin nor oath required. For personal study only.
✦ Synopsis
The magnitude of drug±drug interactions in vitro involving competitive inhibition of cytochrome (CYP) isozymes by newer antidepressants can theoretically be shown to be dependent upon several factors. These include the concentration of both the substrate and inhibitor, the anity of the inhibitor for the inhibited isozyme, and an inhibition constant. The purpose of this study was to compare the results from three human drug interaction studies with theoretical considerations and the results from in vitro studies. Of special interest was the relationship between dose or concentration of an enzyme inhibitor and the change in the plasma concentration of a co-administered drug. Observed data were ®t to equations using linear regression and nonlinear least squares regression analysis. All three human data sets demonstrated a linear dose or concentration dependency in the magnitude of the observed drug± drug interaction. The results draw attention to the dose dependent nature of drug±drug interactions. As the dose of antidepressant is under clinician control, guidelines are suggested to minimize the clinical impact of antidepressant drug interactions.
📜 SIMILAR VOLUMES
The virtually universal family of P-450 isozymes contribute to the regulation of cell growth by modulating the levels of steroids and other lipid messengers for cytoplasmic and nuclear processes, including gene expression. In microsomes from rat liver cells, the concentration (ϳ1 nmole/mg protein) o
## Abstract The concepts of drug development have evolved over the last few decades. Although number of novel chemical entitities belonging to varied classes have made it to the market, the process of drug development is challenging, intertwined as it is with complexities and uncertainities. The in
A great challenge to the continuing search for more efficient and specific anticancer drugs is the unified response by tumor cells to rid themselves of these agents, a process loosely labeled multidrug resistance. While multidrug resistance has now become synonymous with the P-glycoprotein (P-gp) dr